Skip to main content
  • FDA Approves TAVR in Low-Risk Patients

    The U.S. Food and Drug Administration (FDA) has approved transcatheter aortic valve replacement (TAVR) for patients with severe symptomatic aortic stenosis who are at low risk for surgical mortality.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details